513 related articles for article (PubMed ID: 32296970)
21. Immune checkpoint inhibitor myocarditis: elucidating the spectrum of disease through endomyocardial biopsy.
Palaskas NL; Segura A; Lelenwa L; Siddiqui BA; Subudhi SK; Lopez-Mattei J; Durand JB; Deswal A; Zhao B; Maximilian Buja L; Iliescu C
Eur J Heart Fail; 2021 Oct; 23(10):1725-1735. PubMed ID: 34114291
[TBL] [Abstract][Full Text] [Related]
22. Acute Myocarditis by Immune Checkpoint Inhibitor Identified by Quantitative Pixel-Wise Analysis of Native T1 Mapping.
Kato S; Fukui K; Kodama S; Azuma M; Nakayama N; Kishimoto M; Iwasawa T; Kimura K; Tamura K; Utsunomiya D
Circ Cardiovasc Imaging; 2021 May; 14(5):e012177. PubMed ID: 33951932
[No Abstract] [Full Text] [Related]
23. Electrocardiographic features of immune checkpoint inhibitor associated myocarditis.
Zlotoff DA; Hassan MZO; Zafar A; Alvi RM; Awadalla M; Mahmood SS; Zhang L; Chen CL; Ederhy S; Barac A; Banerji D; Jones-O'Connor M; Murphy SP; Armanious M; Forrestal BJ; Kirchberger MC; Coelho-Filho OR; Rizvi MA; Sahni G; Mandawat A; Tocchetti CG; Hartmann S; Gilman HK; Zatarain-Nicolás E; Mahmoudi M; Gupta D; Sullivan R; Ganatra S; Yang EH; Heinzerling LM; Thuny F; Zubiri L; Reynolds KL; Cohen JV; Lyon AR; Groarke J; Thavendiranathan P; Nohria A; Fradley MG; Neilan TG
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33653803
[TBL] [Abstract][Full Text] [Related]
24. Immune checkpoint inhibitor-associated myasthenia gravis, myositis, and myocarditis overlap syndrome.
Lipe DN; Galvis-Carvajal E; Rajha E; Wechsler AH; Gaeta S
Am J Emerg Med; 2021 Aug; 46():51-55. PubMed ID: 33721590
[TBL] [Abstract][Full Text] [Related]
25. Immune checkpoint inhibitor-associated myocarditis: from pathophysiology to rechallenge of therapy - a narrative review.
Tedeschi A; Camilli M; Ammirati E; Gentile P; Palazzini M; Conti N; Verde A; Masciocco G; Foti G; Giannattasio C; Garascia A
Future Cardiol; 2023 Feb; 19(2):91-103. PubMed ID: 37078438
[TBL] [Abstract][Full Text] [Related]
26. Routine assessment of cardiotoxicity in patients undergoing long-term immune checkpoint inhibitor therapy.
Tamura Y; Tamura Y; Yamada K; Taniguchi H; Iwasawa J; Yada H; Kawamura A
Heart Vessels; 2022 Nov; 37(11):1859-1865. PubMed ID: 35633369
[TBL] [Abstract][Full Text] [Related]
27. Coronary and aortic calcification are associated with cardiovascular events on immune checkpoint inhibitor therapy.
Schiffer WB; Deych E; Lenihan DJ; Zhang KW
Int J Cardiol; 2021 Jan; 322():177-182. PubMed ID: 32800916
[TBL] [Abstract][Full Text] [Related]
28. Successful management of camrelizumab-induced immune-checkpoint-inhibitors-related myocarditis.
Long HD; Du YP; Wang LY; Liu GC; Liang SX; Zeng ZH; Lin YE
J Oncol Pharm Pract; 2024 Apr; 30(3):597-604. PubMed ID: 38043937
[TBL] [Abstract][Full Text] [Related]
29. Inflammatory Myositis in Cancer Patients Receiving Immune Checkpoint Inhibitors.
Aldrich J; Pundole X; Tummala S; Palaskas N; Andersen CR; Shoukier M; Abdel-Wahab N; Deswal A; Suarez-Almazor ME
Arthritis Rheumatol; 2021 May; 73(5):866-874. PubMed ID: 33258544
[TBL] [Abstract][Full Text] [Related]
30. Prospective screening for myocarditis in cancer patients treated with immune checkpoint inhibitors.
Furukawa A; Tamura Y; Taniguchi H; Kawamura A; Nagase S; Hayashi A; Tada Y; Sase K; Hatake K
J Cardiol; 2023 Jan; 81(1):63-67. PubMed ID: 35953399
[TBL] [Abstract][Full Text] [Related]
31. Cardiotoxicity of Immune Checkpoint Inhibitors.
Patel RP; Parikh R; Gunturu KS; Tariq RZ; Dani SS; Ganatra S; Nohria A
Curr Oncol Rep; 2021 May; 23(7):79. PubMed ID: 33937956
[TBL] [Abstract][Full Text] [Related]
32. Value of troponin T versus I in the diagnosis of immune checkpoint inhibitor-related myocarditis and myositis: rechallenge?
Rossi VA; Gawinecka J; Dimitriou F; von Eckardstein A; Dummer R; Ruschitzka F; Matter CM
ESC Heart Fail; 2023 Aug; 10(4):2680-2685. PubMed ID: 37021424
[TBL] [Abstract][Full Text] [Related]
33. A closer look at immune-mediated myocarditis in the era of combined checkpoint blockade and targeted therapies.
Guo CW; Alexander M; Dib Y; Lau PKH; Weppler AM; Au-Yeung G; Lee B; Khoo C; Mooney D; Joshi SB; Creati L; Sandhu S
Eur J Cancer; 2020 Jan; 124():15-24. PubMed ID: 31707280
[TBL] [Abstract][Full Text] [Related]
34. Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis.
Li M; Sack JS; Rahma OE; Hodi FS; Zucker SD; Grover S
Cancer; 2020 Dec; 126(23):5088-5097. PubMed ID: 32888341
[TBL] [Abstract][Full Text] [Related]
35. Immune checkpoint-mediated psoriasis: A multicenter European study of 115 patients from the European Network for Cutaneous Adverse Event to Oncologic Drugs (ENCADO) group.
Nikolaou V; Sibaud V; Fattore D; Sollena P; Ortiz-Brugués A; Giacchero D; Romano MC; Riganti J; Lallas K; Peris K; Voudouri D; Lallas A; Fabbrocini G; Lazaridou E; Carrera C; Annunziata MC; Rossi E; Patri A; Rigopoulos D; Stratigos AJ; Apalla Z
J Am Acad Dermatol; 2021 May; 84(5):1310-1320. PubMed ID: 33279646
[TBL] [Abstract][Full Text] [Related]
36. Immunomodulatory treatment of immune checkpoint inhibitor-induced myocarditis: Pathway toward precision-based therapy.
Balanescu DV; Donisan T; Palaskas N; Lopez-Mattei J; Kim PY; Buja LM; McNamara DM; Kobashigawa JA; Durand JB; Iliescu CA
Cardiovasc Pathol; 2020; 47():107211. PubMed ID: 32268262
[TBL] [Abstract][Full Text] [Related]
37. A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor-Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention.
Wei SC; Meijers WC; Axelrod ML; Anang NAS; Screever EM; Wescott EC; Johnson DB; Whitley E; Lehmann L; Courand PY; Mancuso JJ; Himmel LE; Lebrun-Vignes B; Wleklinski MJ; Knollmann BC; Srinivasan J; Li Y; Atolagbe OT; Rao X; Zhao Y; Wang J; Ehrlich LIR; Sharma P; Salem JE; Balko JM; Moslehi JJ; Allison JP
Cancer Discov; 2021 Mar; 11(3):614-625. PubMed ID: 33257470
[TBL] [Abstract][Full Text] [Related]
38. Role of Biomarkers in the Management of Immune-Checkpoint Inhibitor-Related Myocarditis.
Vasbinder A; Ismail A; Salem JE; Hayek SS
Curr Cardiol Rep; 2023 Sep; 25(9):959-967. PubMed ID: 37436648
[TBL] [Abstract][Full Text] [Related]
39. Myocarditis in a patient treated with Nivolumab and PROSTVAC: a case report.
Monge C; Maeng H; Brofferio A; Apolo AB; Sathya B; Arai AE; Gulley JL; Bilusic M
J Immunother Cancer; 2018 Dec; 6(1):150. PubMed ID: 30563577
[TBL] [Abstract][Full Text] [Related]
40. Immune Checkpoint Inhibitor (ICI)-Related Cardiotoxicity.
Zarifa A; Lopez-Mattei J; Palaskas NL; Iliescu C; Durand JB; Kim PY
Adv Exp Med Biol; 2021; 1342():377-387. PubMed ID: 34972975
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
